CoChat
Sign Up
Cited by 38Veterinary Oncology ResearchHuman-Animal Interaction StudiesVeterinary Medicine and Surgery

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Canine Cancer: Strategies in Experimental Therapeutics

Open access
Thamm, Douglas H.·2019·Frontiers in Oncology
DOI 10.3389/fonc.2019.01257PMC PMC6873901
Open this paper in CoChat — free accountOpen PDF

Abstract

Cancer is the most common cause of death in adult dogs. Many features of spontaneously developing tumors in pet dogs contribute to their potential utility as a human disease model. These include similar environmental exposures, similar clonal evolution as it applies to important factors such as immune avoidance, a favorable body size for imaging and serial biopsy, and a relatively contracted time course of disease progression, which makes evaluation of temporal endpoints such as progression free or overall survival feasible in a comparatively short time frame. These criteria have been leveraged to evaluate novel local therapies, demonstrate proof of tumor target inhibition or tumor localization, evaluate potential antimetastatic approaches, and assess the efficacy, safety and immune effects of a variety of immune-based therapeutics. Some of these canine proof of concept studies have been instrumental in informing subsequent human clinical trials. This review will cover key aspects of clinical trials in dogs with spontaneous neoplasia, with examples of how these studies have contributed to human cancer therapeutic development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2019.01257

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 128

  1. Johnson, 2001, Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials, Br J Cancer, 84, 1424, 10.1054/bjoc.2001.1796 · DOI
  2. Paoloni, 2008, Translation of new cancer treatments from pet dogs to humans, Nat Rev Cancer, 8, 147, 10.1038/nrc2273 · DOI · Paper page
  3. Fleming, 2011, Mortality in North American dogs from 1984 to 2004: an investigation into age-, size-, and breed-related causes of death, J Vet Intern Med, 25, 187, 10.1111/j.1939-1676.2011.0695.x · DOI
  4. Alvarez, 2014, Naturally occurring cancers in dogs: insights for translational genetics and medicine, ILAR J, 55, 16, 10.1093/ilar/ilu010 · DOI
  5. Leblanc, 2016, Defining the value of a comparative approach to cancer drug development, Clin Cancer Res, 22, 2133, 10.1158/1078-0432.CCR-15-2347 · DOI
  6. Vail, 2004, Spontaneously occurring tumors in companion animals as models for drug development, 259, 10.1007/978-1-59259-739-0_12 · DOI
  7. Ladue, 2001, Toxicity criteria of the veterinary radiation therapy oncology group, Vet Radiol Ultrasound, 42, 475, 10.1111/j.1740-8261.2001.tb00973.x · DOI
  8. 2016, Veterinary Cooperative Oncology Group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1, Vet Comp Oncol, 14, 417, 10.1111/vco.283 · DOI
  9. Vail, 2010, Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)–a Veterinary Cooperative Oncology Group (VCOG) consensus document, Vet Comp Oncol., 8, 28, 10.1111/j.1476-5829.2009.00200.x · DOI
  10. Nguyen, 2015, Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document, Vet Comp Oncol, 13, 176, 10.1111/vco.12032 · DOI
  11. Cline, 1990, Immunohistochemical detection of a hypoxia marker in spontaneous canine tumours, Br J Cancer, 62, 925, 10.1038/bjc.1990.411 · DOI
  12. Zeman, 1993, The relationship between proliferative and oxygenation status in spontaneous canine tumors, Int J Radiat Oncol Biol Phys, 27, 891, 10.1016/0360-3016(93)90465-8 · DOI
  13. Cline, 1994, Distribution of the hypoxia marker CCI-103F in canine tumors, Int J Radiat Oncol Biol Phys, 28, 921, 10.1016/0360-3016(94)90113-9 · DOI
  14. Raleigh, 1995, Distribution of hypoxia and proliferation associated markers in spontaneous canine tumors, Acta Oncol, 34, 345, 10.3109/02841869509093987 · DOI
  15. Cline, 1997, Quantification of CCI-103F labeling heterogeneity in canine solid tumors, Int J Radiat Oncol Biol Phys, 37, 655, 10.1016/S0360-3016(96)00559-7 · DOI
  16. Thrall, 1997, Hypoxia marker labeling in tumor biopsies: quantification of labeling variation and criteria for biopsy sectioning, Radiother Oncol, 44, 171, 10.1016/S0167-8140(97)01931-2 · DOI
  17. Zachos, 2001, Interstitial fluid pressure and blood flow in canine osteosarcoma and other tumors, Clin Orthop Relat Res, 230, 10.1097/00003086-200104000-00034 · DOI
  18. Larue, 1989, Limb-sparing treatment for osteosarcoma in dogs, J Am Vet Med Assoc, 195, 1734
  19. Thrall, 1990, Radiotherapy prior to cortical allograft limb sparing in dogs with osteosarcoma: a dose response assay, Int J Radiat Oncol Biol Phys, 18, 1351, 10.1016/0360-3016(90)90308-7 · DOI
  20. Withrow, 1993, Intra-arterial cisplatin with or without radiation in limb-sparing for canine osteosarcoma, Cancer, 71, 2484, 10.1002/1097-0142(19930415)71:8<2484::AID-CNCR2820710810>3.0.CO;2-D · DOI
  21. Withrow, 2010, Cross talk from pets to people: translational osteosarcoma treatments, ILAR J, 51, 208, 10.1093/ilar.51.3.208 · DOI
  22. Lascelles, 2005, Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma, Ann Surg Oncol, 12, 1073, 10.1245/ASO.2005.01.011 · DOI
  23. Jeys, 2007, Post operative infection and increased survival in osteosarcoma patients: are they associated?, Ann Surg Oncol, 14, 2887, 10.1245/s10434-007-9483-8 · DOI
  24. Sottnik, 2010, Chronic bacterial osteomyelitis suppression of tumor growth requires innate immune responses, Cancer Immunol Immunother, 59, 367, 10.1007/s00262-009-0755-y · DOI
  25. Gillette, 1975, Endothelial repair of radiation damage following beta irradiation, Radiology, 116, 175, 10.1148/116.1.175 · DOI
  26. Fike, 1979, Repair of sublethal radiation damage by capillaries, Int J Radiat Oncol Biol Phys, 5, 339, 10.1016/0360-3016(79)91213-6 · DOI
  27. Gavin, 1982, Radiation response of the canine cardiovascular system, Radiat Res, 90, 489, 10.2307/3575726 · DOI
  28. Gillette, 1985, Isoeffect curves for radiation-induced cardiomyopathy in the dog, Int J Radiat Oncol Biol Phys, 11, 2091, 10.1016/0360-3016(85)90089-6 · DOI
  29. Hoopes, 1985, The pathogenesis of radiation nephropathy in the dog, Radiat Res, 104, 406, 10.2307/3576600 · DOI
  30. Powers, 1987, Late radiation response of the canine trachea with change in dose per fraction, Int J Radiat Oncol Biol Phys, 13, 1673, 10.1016/0360-3016(87)90164-7 · DOI
  31. Ahmadu-Suka, 1988, Exocrine pancreatic function following intraoperative irradiation of the canine pancreas, Cancer, 62, 1091, 10.1002/1097-0142(19880915)62:6<1091::AID-CNCR2820620611>3.0.CO;2-A · DOI
  32. Ching, 1990, Radiation-induced ocular injury in the dog: a histological study, Int J Radiat Oncol Biol Phys, 19, 321, 10.1016/0360-3016(90)90540-Z · DOI
  33. Gillette, 1991, Early radiation response of the canine heart and lung, Radiat Res, 125, 34, 10.2307/3577979 · DOI
  34. Powers, 1991, Muscle injury following experimental intraoperative irradiation, Int J Radiat Oncol Biol Phys, 20, 463, 10.1016/0360-3016(91)90058-C · DOI
  35. Gillette, 1992, Response of canine soft tissue sarcomas to radiation or radiation plus hyperthermia: a randomized phase II study, Int J Hyperthermia, 8, 309, 10.3109/02656739209021786 · DOI
  36. McChesney, 1989, Response of the canine lung to fractionated irradiation: pathologic changes and isoeffect curves, Int J Radiat Oncol Biol Phys, 16, 125, 10.1016/0360-3016(89)90019-9 · DOI
  37. Mackie, 2003, Image guidance for precise conformal radiotherapy, Int J Radiat Oncol Biol Phys, 56, 89, 10.1016/S0360-3016(03)00090-7 · DOI
  38. Forrest, 2004, The utility of megavoltage computed tomography images from a helical tomotherapy system for setup verification purposes, Int J Radiat Oncol Biol Phys, 60, 1639, 10.1016/j.ijrobp.2004.08.016 · DOI
  39. Thrall, 2006, Changes in tumour oxygenation during fractionated hyperthermia and radiation therapy in spontaneous canine sarcomas, Int J Hyperthermia, 22, 365, 10.1080/02656730600836386 · DOI
  40. Chi, 2011, Comparison of genomics and functional imaging from canine sarcomas treated with thermoradiotherapy predicts therapeutic response and identifies combination therapeutics, Clin Cancer Res, 17, 2549, 10.1158/1078-0432.CCR-10-2583 · DOI
  41. Thrall, 2012, Thermal dose fractionation affects tumour physiological response, Int J Hyperthermia, 28, 431, 10.3109/02656736.2012.689087 · DOI
  42. Hershey, 1999, Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model, Clin Cancer Res, 5, 2653
  43. Rodriguez, 2010, Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs, J Aerosol Med Pulm Drug Deliv, 23, 197, 10.1089/jamp.2009.0773 · DOI
  44. Khanna, 1997, Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases, Cancer, 79, 1409, 10.1002/(SICI)1097-0142(19970401)79:7<1409::AID-CNCR19>3.0.CO;2-3 · DOI
  45. Dow, 1998, In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma, J Clin Invest, 101, 2406, 10.1172/JCI510 · DOI
  46. Thamm, 2003, Intralesional lipid-complexed cytokine/superantigen immunogene therapy for spontaneous canine tumors, Cancer Immunol Immunother, 52, 473, 10.1007/s00262-003-0387-6 · DOI
  47. Finocchiaro, 2011, Cytokine-enhanced vaccine and interferon-beta plus suicide gene as combined therapy for spontaneous canine sarcomas, Res Vet Sci, 91, 230, 10.1016/j.rvsc.2010.12.012 · DOI
  48. Westberg, 2013, Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma, J Immunother, 36, 350, 10.1097/CJI.0b013e31829d8a1b · DOI
  49. Theon, 1991, Localized thermo-cisplatin therapy: a pilot study in spontaneous canine and feline tumours, Int J Hyperthermia, 7, 881, 10.3109/02656739109056456 · DOI
  50. Kitchell, 1994, Intralesional implant for treatment of primary oral malignant melanoma in dogs, J Am Vet Med Assoc, 204, 229, 10.2460/javma.1994.204.02.229 · DOI
  51. Theon, 1994, Concurrent irradiation and intratumoral chemotherapy with cisplatin: a pilot study in dogs with spontaneous tumors, Int J Radiat Oncol Biol Phys, 29, 1027, 10.1016/0360-3016(94)90398-0 · DOI
  52. Kitchell, 1995, Intralesional sustained-release chemotherapy with therapeutic implants for treatment of canine sun-induced squamous cell carcinoma, Eur J Cancer, 2093, 10.1016/0959-8049(95)00446-7 · DOI
  53. Venable, 2012, Effects of intratumoral administration of a hyaluronan-cisplatin nanoconjugate to five dogs with soft tissue sarcomas, Am J Vet Res, 73, 1969, 10.2460/ajvr.73.12.1969 · DOI
  54. London, 1999, Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit, Exp Hematol, 27, 689, 10.1016/S0301-472X(98)00075-7 · DOI
  55. Decker, 2015, Homologous mutation to human BRAF V600E is common in naturally occurring canine bladder cancer–evidence for a relevant model system and urine-based diagnostic test, Mol Cancer Res, 13, 993, 10.1158/1541-7786.MCR-14-0689 · DOI
  56. Mochizuki, 2017, Sequence analysis of RAS and RAF mutation hot spots in canine carcinoma, Vet Comp Oncol, 15, 1598, 10.1111/vco.12275 · DOI
  57. Liao, 2002, Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors, Blood, 100, 585, 10.1182/blood-2001-12-0350 · DOI
  58. London, 2003, Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies, Clin Cancer Res, 9, 2755
  59. Pryer, 2003, Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors, Clin Cancer Res, 9, 5729
  60. London, 2009, Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision, Clin Cancer Res, 15, 3856, 10.1158/1078-0432.CCR-08-1860 · DOI
  61. London, 2014, Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study, PLoS ONE, 9, e87585, 10.1371/journal.pone.0087585 · DOI
  62. Honigberg, 2010, The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy, Proc Natl Acad Sci USA, 107, 13075, 10.1073/pnas.1004594107 · DOI · Paper page
  63. Paoloni, 2009, Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature, PLoS ONE, 4, e4972, 10.1371/journal.pone.0004972 · DOI
  64. Thamm, 2005, Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation, Clin Cancer Res, 11, 4827, 10.1158/1078-0432.CCR-04-2510 · DOI
  65. Toso, 2002, Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma, J Clin Oncol, 20, 142, 10.1200/JCO.20.1.142 · DOI
  66. Hauck, 2006, Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors, Clin Cancer Res, 12, 4004, 10.1158/1078-0432.CCR-06-0226 · DOI
  67. Barnard, 2014, Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma, Autophagy, 10, 1415, 10.4161/auto.29165 · DOI
  68. Burton, 2018, NCI Comparative Oncology Program testing of non-camptothecin indenoisoquinoline topoisomerase i inhibitors in naturally occurring canine lymphoma, Clin Cancer Res, 24, 5830, 10.1158/1078-0432.CCR-18-1498 · DOI
  69. Kurzman, 1995, Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin, Clin Cancer Res, 1, 1595
  70. Vail, 1995, Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial, Clin Cancer Res, 1, 1165
  71. Kurzman, 1999, In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells, Cancer Biother Radiopharm, 14, 121, 10.1089/cbr.1999.14.121 · DOI
  72. Meyers, 2005, Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate, J Clin Oncol, 23, 2004, 10.1200/JCO.2005.06.031 · DOI
  73. Vail, 2002, STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial, Cancer Chemother Pharmacol, 50, 131, 10.1007/s00280-002-0469-8 · DOI
  74. Borgatti, 2017, Safe and effective sarcoma therapy through bispecific targeting of EGFR and uPAR, Mol Cancer Ther, 16, 956, 10.1158/1535-7163.MCT-16-0637 · DOI
  75. Itoh, 2009, Evaluation of immunological status in tumor-bearing dogs, Vet Immunol Immunopathol, 132, 85, 10.1016/j.vetimm.2009.04.020 · DOI
  76. De Andres, 2013, Increased levels of interleukins 8 and 10 as findings of canine inflammatory mammary cancer, Vet Immunol Immunopathol, 152, 245, 10.1016/j.vetimm.2012.12.010 · DOI
  77. Kim, 2014, Interleukin-8 promotes canine hemangiosarcoma growth by regulating the tumor microenvironment, Exp Cell Res, 323, 155, 10.1016/j.yexcr.2014.02.020 · DOI
  78. Troyer, 2017, Exosomes from osteosarcoma and normal osteoblast differ in proteomic cargo and immunomodulatory effects on T cells, Exp Cell Res, 358, 369, 10.1016/j.yexcr.2017.07.011 · DOI
  79. Biller, 2007, Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer, Vet Immunol Immunopathol, 116, 69, 10.1016/j.vetimm.2006.12.002 · DOI
  80. O'Neill, 2009, Changes in regulatory T cells in dogs with cancer and associations with tumor type, J Vet Intern Med, 23, 875, 10.1111/j.1939-1676.2009.0333.x · DOI
  81. Biller, 2010, Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma, J Vet Intern Med, 24, 1118, 10.1111/j.1939-1676.2010.0557.x · DOI
  82. Goulart, 2012, Identification of myeloid derived suppressor cells in dogs with naturally occurring cancer, PLoS ONE, 7, e33274, 10.1371/journal.pone.0033274 · DOI
  83. Sherger, 2012, Identification of myeloid derived suppressor cells in the peripheral blood of tumor bearing dogs, BMC Vet Res, 8, 209, 10.1186/1746-6148-8-209 · DOI
  84. Goulart, 2019, Phenotypic and transcriptomic characterization of canine myeloid-derived suppressor cells, Sci Rep, 9, 3574, 10.1038/s41598-019-40285-3 · DOI
  85. Beirao, 2015, Canine mammary cancer cells direct macrophages toward an intermediate activation state between M1/M2, BMC Vet Res, 11, 151, 10.1186/s12917-015-0473-y · DOI
  86. Regan, 2017, Role of monocyte recruitment in hemangiosarcoma metastasis in dogs, Vet Comp Oncol, 15, 1309, 10.1111/vco.12272 · DOI
  87. Monteiro, 2018, Tumour-associated macrophages: relation with progression and invasiveness, and assessment of M1/M2 macrophages in canine mammary tumours, Vet J, 234, 119, 10.1016/j.tvjl.2018.02.016 · DOI
  88. Seung, 2018, CD204-expressing tumor-associated macrophages are associated with malignant, high-grade, and hormone receptor-negative canine mammary gland tumors, Vet Pathol, 55, 417, 10.1177/0300985817750457 · DOI
  89. Maekawa, 2014, Expression of PD-L1 on canine tumor cells and enhancement of IFN-gamma production from tumor-infiltrating cells by PD-L1 blockade, PLoS ONE, 9, e98415, 10.1371/journal.pone.0098415 · DOI
  90. Maekawa, 2016, Immunohistochemical analysis of PD-L1 expression in canine malignant cancers and PD-1 expression on lymphocytes in canine oral melanoma, PLoS ONE, 11, e0157176, 10.1371/journal.pone.0157176 · DOI
  91. Ambrosius, 2018, Quantification and prognostic value of programmed cell death ligand-1 expression in dogs with diffuse large B-cell lymphoma, Am J Vet Res, 79, 643, 10.2460/ajvr.79.6.643 · DOI
  92. Hartley, 2018, Checkpoint molecule expression by B and T cell lymphomas in dogs, Vet Comp Oncol, 16, 352, 10.1111/vco.12386 · DOI
  93. Chand, 2019, Frequency and risk factors for liver disease following pancreatitis: a population-based cohort study, Dig Liver Dis, 51, 551, 10.1016/j.dld.2018.11.001 · DOI
  94. Bech-Nielsen, 1977, The effect of BCG on in vitro immune reactivity and clinical course in dogs treated surgically for osteosarcoma, Eur J Cancer, 13, 33, 10.1016/0014-2964(77)90227-4 · DOI
  95. Bostock, 1978, Intravenous BCG therapy of mammary carcinoma in bitches after surgical excision of the primary tumour, Eur J Cancer, 14, 879, 10.1016/0014-2964(78)90104-4 · DOI
  96. Meyer, 1982, Canine osteogenic sarcoma treated by amputation and MER: an adverse effect of splenectomy on survival, Cancer, 49, 1613, 10.1002/1097-0142(19820415)49:8<1613::AID-CNCR2820490814>3.0.CO;2-R · DOI
  97. Parodi, 1983, Intratumoral BCG and Corynebacterium parvum therapy of canine mammary tumours before radical mastectomy, Cancer Immunol Immunother, 15, 172, 10.1007/BF00199160 · DOI
  98. Henry, 2007, Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs, Am J Vet Res, 68, 1246, 10.2460/ajvr.68.11.1246 · DOI
  99. Macewen, 1999, Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor, Clin Cancer Res, 5, 4249
  100. Moore, 1991, Preclinical study of sequential tumor necrosis factor and interleukin 2 in the treatment of spontaneous canine neoplasms, Cancer Res, 51, 233
  101. Mito, 2010, IFNγ markedly cooperates with intratumoral dendritic cell vaccine in dog tumor models, Cancer Res, 70, 7093, 10.1158/0008-5472.CAN-10-0600 · DOI
  102. Henson, 2011, Immunotherapy with autologous tumour antigen-coated microbeads (large multivalent immunogen), IL-2 and GM-CSF in dogs with spontaneous B-cell lymphoma, Vet Comp Oncol, 9, 95, 10.1111/j.1476-5829.2010.00234.x · DOI
  103. Konietschke, 2012, Palliative intralesional interleukin-2 treatment in dogs with urinary bladder and urethral carcinomas, In Vivo, 26, 931
  104. Haagsman, 2013, The effect of interleukin-2 on canine peripheral nerve sheath tumours after marginal surgical excision: a double-blind randomized study, BMC Vet Res, 9, 155, 10.1186/1746-6148-9-155 · DOI
  105. Ziekman, 2013, Intratumoural interleukin-2 therapy can induce regression of non-resectable mastocytoma in dogs, Anticancer Res, 33, 161
  106. Finocchiaro, 2015, Cytokine-enhanced vaccine and interferon-beta plus suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma, Hum Gene Ther, 26, 367, 10.1089/hum.2014.130 · DOI
  107. Monjazeb, 2016, Blocking indolamine-2,3-dioxygenase rebound immune suppression boosts antitumor effects of radio-immunotherapy in murine models and spontaneous canine malignancies, Clin Cancer Res, 22, 4328, 10.1158/1078-0432.CCR-15-3026 · DOI
  108. Cicchelero, 2017, Intratumoural interleukin 12 gene therapy stimulates the immune system and decreases angiogenesis in dogs with spontaneous cancer, Vet Comp Oncol, 15, 1187, 10.1111/vco.12255 · DOI
  109. Paoloni, 2015, Defining the pharmacodynamic profile and therapeutic index of NHS-IL12 immunocytokine in dogs with malignant melanoma, PLoS ONE, 10, e0129954, 10.1371/journal.pone.0129954 · DOI
  110. London, 2017, KTN0158, a humanized anti-KIT monoclonal antibody, demonstrates biologic activity against both normal and malignant canine mast cells, Clin Cancer Res, 23, 2565, 10.1158/1078-0432.CCR-16-2152 · DOI
  111. Maekawa, 2017, A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma, Sci Rep, 7, 8951, 10.1038/s41598-017-09444-2 · DOI
  112. Hogge, 1998, Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer, Hum Gene Ther, 9, 1851, 10.1089/hum.1998.9.13-1851 · DOI
  113. Turek, 2007, Human granulocyte-macrophage colony-stimulating factor DNA cationic-lipid complexed autologous tumour cell vaccination in the treatment of canine B-cell multicentric lymphoma, Vet Comp Oncol, 5, 219, 10.1111/j.1476-5829.2007.00128.x · DOI
  114. Bird, 2011, An autologous dendritic cell canine mammary tumor hybrid-cell fusion vaccine, Cancer Immunol Immunother, 60, 87, 10.1007/s00262-010-0921-2 · DOI
  115. Sorenmo, 2011, CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma, PLoS ONE, 6, e24167, 10.1371/journal.pone.0024167 · DOI
  116. Marconato, 2014, Randomized, placebo-controlled, double-blinded chemoimmunotherapy clinical trial in a pet dog model of diffuse large B-cell lymphoma, Clin Cancer Res, 20, 668, 10.1158/1078-0432.CCR-13-2283 · DOI
  117. U'Ren, 2007, Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma, J Vet Intern Med, 21, 113, 10.1111/j.1939-1676.2007.tb02936.x · DOI
  118. Bergman, 2003, Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial, Clin Cancer Res, 9, 1284
  119. Bergman, 2006, Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center, Vaccine, 24, 4582, 10.1016/j.vaccine.2005.08.027 · DOI
  120. Kamstock, 2007, Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma, Cancer Immunol Immunother, 56, 1299, 10.1007/s00262-007-0282-7 · DOI
  121. Gavazza, 2013, Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B-cell lymphoma, Hum Gene Ther, 24, 728, 10.1089/hum.2013.112 · DOI
  122. Mie, 2016, Change in peripheral blood lymphocyte count in dogs following adoptive immunotherapy using lymphokine-activated T killer cells combined with palliative tumor resection, Vet Immunol Immunopathol, 177, 58, 10.1016/j.vetimm.2016.06.007 · DOI
  123. O'Connor, 2012, Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy, Sci Rep, 2, 249, 10.1038/srep00249 · DOI
  124. Hwang, 2018, Oncolytic reovirus therapy: pilot study in dogs with spontaneously occurring tumours, Vet Comp Oncol, 16, 229, 10.1111/vco.12361 · DOI
  125. Naik, 2018, Comparative oncology evaluation of intravenous recombinant oncolytic vesicular stomatitis virus therapy in spontaneous canine cancer, Mol Cancer Ther, 17, 316, 10.1158/1535-7163.MCT-17-0432 · DOI
  126. Panjwani, 2016, Feasibility and safety of RNA-transfected CD20-specific chimeric antigen receptor T cells in dogs with spontaneous B Cell lymphoma, Mol Ther, 24, 1602, 10.1038/mt.2016.146 · DOI
  127. Walsh, 2000, A phase I study using direct combination DNA injections for the immunotherapy of metastatic melanoma, Univ Colorado Cancer Center Clinical Trial Hum Gene Ther, 11, 1355, 10.1089/10430340050032447 · DOI
  128. Yuan, 2013, Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma, J Immunother Cancer, 1, 20, 10.1186/2051-1426-1-20 · DOI

Cited by

Sorted by citations

See all 38

Metadata

Authors
Thamm, D. H.
Affiliations
University of Colorado Cancer Center (US)
Corresponding author
Thamm, Douglas H.
ORCID
Thamm, Douglas H.
Venue
Frontiers in Oncology
Publisher
Frontiers Media SA
Published
2019-11-15
Volume
9
Pages
1257-1257
ISSN
2234-943X (ISSN-L)
DOI
10.3389/fonc.2019.01257
PMC
PMC6873901
OpenAlex
W2985271011
Cited by
38
References
3
Citations by year
2026: 4 · 2025: 2 · 2024: 5 · 2023: 8 · 2022: 2 · 2021: 10 · 2020: 7
FWCI
0.80
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Veterinary › Small Animals › Veterinary Oncology Research
  • Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Human-Animal Interaction Studies
  • Health Sciences › Veterinary › Small Animals › Veterinary Medicine and Surgery
Keywords
canine cancer, spontaneous tumors, experimental therapeutics, immunotherapy, anti-metastatic therapy, proof of concept, translational oncology, progression-free survival, overall survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Canine Cancer: Strategies in Experimental Therapeutics. https://app.cochat.ai/papers/10.3389/fonc.2019.01257
The paper
Thamm, D. H. (2019). Canine Cancer: Strategies in Experimental Therapeutics. Frontiers in Oncology. https://doi.org/10.3389/fonc.2019.01257